Personalized ctDNA test to predict rectal cancer treatment response
Part of Cancer, Digestive system clinical trials.
This trial uses a personalized blood test (ctDNA-MRD) to see how well neoadjuvant therapy works for rectal cancer. If you have stage II or III rectal cancer that can be surgically removed, this study might help guide your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have rectal adenocarcinoma (a type of rectal cancer) confirmed by biopsy
- Your cancer is stage II or III based on MRI scans
- The lower edge of your tumor is within 10 cm of the anal opening
- You have not had any prior cancer treatment for rectal cancer (like radiation, chemo, or surgery)
- You are healthy enough for surgery and can take pills by mouth
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and bevacizumab given before surgery for locally advanced rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes.
This trial uses a special DNA blood test (circulating tumor DNA) to help guide chemotherapy and radiation before surgery for locally advanced rectal cancer. It aims to improve outcomes by tailoring treatment based on the DNA signals from the tumor.
Hear when a new Locally Advanced Rectal Cancer (LARC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.